Prostatic α1-adrenoceptors: new concepts of function, regulation, and intracellular signaling (Q38137877)

29 August 2017

title

Prostatic α1-adrenoceptors: new concepts of function, regulation, and intracellular signaling (English)

1 reference

29 August 2017

2

Christian G Stief

1 reference

29 August 2017

Martin Hennenberg

1

1 reference

29 August 2017

Christian Gratzke

series ordinal

3

1 reference

29 August 2017

publication date

22 August 2013

1 reference

Neurourology and Urodynamics

29 August 2017

published in

1 reference

29 August 2017

volume

33

1 reference

29 August 2017

issue

7

1 reference

29 August 2017

page(s)

1074-1085

1 reference

LUTS treatment: future treatment options

29 August 2017

cites work

1 reference

Lower urinary tract symptoms revisited: a broader clinical perspective

21 January 2018

1 reference

Prostatic alpha 1-adrenoceptors and uroselectivity

21 January 2018

1 reference

Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia

21 January 2018

1 reference

The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: alpha-blockers in the treatment of male voiding dysfunction - how do they work and why do they differ in tolerability?

21 January 2018

1 reference

The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic followup of transurethral resection of prostate for bladder outlet obstruction

21 January 2018

1 reference

The long-term outcome of medical therapy for BPH.

21 January 2018

1 reference

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

21 January 2018

1 reference

The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study

21 January 2018

1 reference

Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials

21 January 2018

1 reference

Effects of alpha 1-adrenergic receptor subtype selective antagonists on lower urinary tract function in rats with bladder outlet obstruction

21 January 2018

1 reference

Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system

21 January 2018

1 reference

Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial

21 January 2018

1 reference

Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract

21 January 2018

1 reference

Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate

21 January 2018

1 reference

β-Arrestin-mediated receptor trafficking and signal transduction

21 January 2018

1 reference

Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling

21 January 2018

1 reference

Alpha1-adrenoceptor subtypes and lower urinary tract symptoms

21 January 2018

1 reference

Ten commercial antibodies for alpha-1-adrenergic receptor subtypes are nonspecific

21 January 2018

1 reference

The alpha1A-adrenoceptor gene is required for the alpha1L-adrenoceptor-mediated response in isolated preparations of the mouse prostate

21 January 2018

1 reference

Identification of alpha 1L-adrenoceptor in mice and its abolition by alpha 1A-adrenoceptor gene knockout

21 January 2018

1 reference

The alpha1L-adrenoceptor is an alternative phenotype of the alpha1A-adrenoceptor

21 January 2018

1 reference

Native profiles of alpha(1A)-adrenoceptor phenotypes in rabbit prostate

21 January 2018

1 reference

What makes the α(1A)-adrenoceptor gene express the α(1L)-adrenoceptor functional phenotype?

21 January 2018

1 reference

Phenotype pharmacology of lower urinary tract α(1)-adrenoceptors.

21 January 2018

1 reference

Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe

21 January 2018

1 reference

Silodosin : a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia

21 January 2018

1 reference

α(1)-Adrenoceptors in the urinary tract

21 January 2018

1 reference

Signal transduction by G-proteins, rho-kinase and protein phosphatase to smooth muscle and non-muscle myosin II.

21 January 2018

1 reference

Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase

21 January 2018

1 reference

Smooth muscle signalling pathways in health and disease

21 January 2018

1 reference

Phosphorylated l-caldesmon is involved in disassembly of actin stress fibers and postmitotic spreading.

21 January 2018

1 reference

Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells.

21 January 2018

1 reference

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction

21 January 2018

1 reference

Pharmacological characterization of isolated human prostate.

21 January 2018

1 reference

Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases

21 January 2018

1 reference

Mitogen-activated protein kinases in cell-cycle control

21 January 2018

1 reference

MAPK signal pathways in the regulation of cell proliferation in mammalian cells

21 January 2018

1 reference

Inhibition of adrenergic human prostate smooth muscle contraction by the inhibitors of c-Jun N-terminal kinase, SP600125 and BI-78D3.

21 January 2018

1 reference

Caldesmon is necessary for maintaining the actin and intermediate filaments in cultured bladder smooth muscle cells

21 January 2018

1 reference

Over expression of smooth muscle specific caldesmon by transfection and intermittent agonist induced contraction alters cellular morphology and restores differentiated smooth muscle phenotype

21 January 2018

1 reference

Effect of long-term partial bladder outlet obstruction on caldesmon isoforms and their correlation with contractile function

21 January 2018

1 reference

Expression and alpha1-adrenoceptor regulation of caldesmon in human prostate smooth muscle

21 January 2018

1 reference

Caldesmon inhibits active crossbridges in unstimulated vascular smooth muscle: an antisense oligodeoxynucleotide approach

21 January 2018

1 reference

Potential for control of detrusor smooth muscle spontaneous rhythmic contraction by cyclooxygenase products released by interstitial cells of Cajal

21 January 2018

1 reference

Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology

21 January 2018

1 reference

Pharmacological characterization of thromboxane and prostanoid receptors in human isolated urinary bladder

21 January 2018

1 reference

Thromboxane A2 induces contraction of human prostate smooth muscle by Rho kinase- and calmodulin-dependent mechanisms

21 January 2018

1 reference

Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation

21 January 2018

1 reference

Correlation between expression of α₁-adrenoceptor subtype mRNA and severity of lower urinary tract symptoms or bladder outlet obstruction in benign prostatic hyperplasia patients.

21 January 2018

1 reference

Expression of alpha1-adrenoceptor subtype mRNA as a predictor of the efficacy of subtype selective alpha1-adrenoceptor antagonists in the management of benign prostatic hyperplasia

21 January 2018

1 reference

Comparison of alpha1Adrenoceptors in the Prostate Capsule of Men with Symptomatic and Asymptomatic Benign Prostatic Hyperplasia

21 January 2018

1 reference

Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human prostate: comparison of benign hypertrophied tissue and non-hypertrophied tissue

21 January 2018

1 reference

Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization

21 January 2018

1 reference

Arresting angiotensin type 1 receptors.

21 January 2018

1 reference

Reciprocal regulation of angiotensin receptor-activated extracellular signal-regulated kinases by beta-arrestins 1 and 2.

21 January 2018

1 reference

Beta-arrestins and cell signaling

21 January 2018

1 reference

Signal switching, crosstalk, and arrestin scaffolds: novel G protein-coupled receptor signaling in cardiovascular disease.

21 January 2018

1 reference

beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor

21 January 2018

1 reference

The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation.

21 January 2018

1 reference

Stable interaction between beta-arrestin 2 and angiotensin type 1A receptor is required for beta-arrestin 2-mediated activation of extracellular signal-regulated kinases 1 and 2.

21 January 2018

1 reference

Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2.

21 January 2018

1 reference

Trafficking of G protein-coupled receptors

21 January 2018

1 reference

Intracellular trafficking of hormone receptors

21 January 2018

1 reference

Regulatory mechanisms of dynamin-dependent endocytosis

21 January 2018

1 reference

Noradrenaline induces binding of Clathrin light chain A to α1-adrenoceptors in the human prostate

21 January 2018

1 reference

Identification of cysteine-rich epidermal growth factor-like domain 1alpha (CRELD1alpha) as a novel alpha1A-adrenoceptor-down-regulating protein and establishment of an alpha1L-adrenoceptor-expressing cell line

21 January 2018

1 reference

Coupling of α1-adrenoceptors to ERK1/2 in the human prostate.

21 January 2018

1 reference

Activation of protein kinase B/Akt by alpha1-adrenoceptors in the human prostate.

21 January 2018

1 reference

Norepinephrine activates P44 and P42 MAPK in human prostate stromal and smooth muscle cells but not in epithelial cells

21 January 2018

1 reference

Mitogen Activated Protein kinase signal transduction pathways in the prostate

21 January 2018

1 reference

Pharmacological and functional characterization of bradykinin B2 receptor in human prostate

21 January 2018

1 reference

The proliferative effect of estradiol on human prostate stromal cells is mediated through activation of ERK.

21 January 2018

1 reference

Mitogenic signaling pathways in airway smooth muscle

21 January 2018

1 reference

Saposin C stimulates growth and invasion, activates p42/44 and SAPK/JNK signaling pathways of MAPK and upregulates uPA/uPAR expression in prostate cancer and stromal cells.

21 January 2018

1 reference

Saw palmetto extract suppresses insulin-like growth factor-I signaling and induces stress-activated protein kinase/c-Jun N-terminal kinase phosphorylation in human prostate epithelial cells

21 January 2018

1 reference

The novel molecule 2-[5-(2-chloroethyl)-2-acetoxy-benzyl]-4-(2-chloroethyl)-phenyl acetate inhibits phosphoinositide 3-kinase/Akt/mammalian target of rapamycin signalling through JNK activation in cancer cells

21 January 2018

1 reference

Inhibition of human prostate cancer cells proliferation by a selective alpha1-adrenoceptor antagonist labedipinedilol-A involves cell cycle arrest and apoptosis

21 January 2018

1 reference

Apoptosis induced by capsaicin in prostate PC-3 cells involves ceramide accumulation, neutral sphingomyelinase, and JNK activation

21 January 2018

1 reference

Phosphorylation of Bcl-2 and activation of caspase-3 via the c-Jun N-terminal kinase pathway in ursolic acid-induced DU145 cells apoptosis

21 January 2018

1 reference

Stress and vascular responses: mitogen-activated protein kinases and activator protein-1 as promising therapeutic targets of vascular remodeling

21 January 2018

1 reference

Mitogen-activated protein kinase signalling pathways in IL-1 beta-dependent rat airway smooth muscle proliferation

21 January 2018

1 reference

Mechanisms of induction of airway smooth muscle hyperplasia by transforming growth factor-beta

21 January 2018

1 reference

Response of bladder smooth muscle cells to obstruction: signal transduction and the role of mechanosensors

21 January 2018

1 reference

Intracellular signaling by Akt: bound to be specific

21 January 2018

1 reference

Recent advances in the protein kinase B signaling pathway

21 January 2018

1 reference

The modulation of vascular ATP-sensitive K+ channel function via the phosphatidylinositol 3-kinase-Akt pathway activated by phenylephrine

21 January 2018

1 reference

Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice

21 January 2018

1 reference

Regulation of cell size and contractile function by AKT in cardiomyocytes.

21 January 2018

1 reference

Dehydroepiandrosterone-induced proliferation of prostatic epithelial cell is mediated by NFKB via PI3K/AKT signaling pathway

21 January 2018

1 reference

Excitation-transcription coupling in smooth muscle

21 January 2018

1 reference

Multiple repressor pathways contribute to phenotypic switching of vascular smooth muscle cells

21 January 2018

1 reference

Excitation-transcription coupling in arterial smooth muscle.

21 January 2018

1 reference

PARP-1 activation in the ERK signaling pathway

21 January 2018

1 reference

Ternary complex factors: prime nuclear targets for mitogen-activated protein kinases

21 January 2018

1 reference

Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis

21 January 2018

1 reference

GRP receptor-mediated immediate early gene expression and transcription factor Elk-1 activation in prostate cancer cells

21 January 2018

1 reference

Silibinin impairs constitutively active TGFalpha-EGFR autocrine loop in advanced human prostate carcinoma cells

21 January 2018

1 reference

Molecular regulation of vascular smooth muscle cell differentiation in development and disease

21 January 2018

1 reference

Small interfering RNA transfection against serum response factor mediates growth inhibition of benign prostatic hyperplasia fibroblasts

21 January 2018

1 reference

Silodosin inhibits noradrenaline-activated transcription factors Elk1 and SRF in human prostate smooth muscle

21 January 2018

1 reference

Mechanistic investigation of the adrenergic induction of ventral prostate hyperplasia in mice

21 January 2018

1 reference

Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia

21 January 2018

1 reference

Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia

21 January 2018

1 reference

Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia.

21 January 2018

1 reference

Induction of prostate apoptosis by alpha1-adrenoceptor antagonists: mechanistic significance of the quinazoline component

21 January 2018

1 reference

Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway

21 January 2018

1 reference

Apoptotic and proliferative index after Alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia

21 January 2018

1 reference

Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate

21 January 2018

1 reference

beta-arrestin-biased agonism at the beta2-adrenergic receptor

21 January 2018

1 reference

Therapeutic potential of β-arrestin- and G protein-biased agonists.

21 January 2018

1 reference

A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/NAU.22467

1 reference

29 August 2017

1 reference